Clinical trials: Renal Transplant Rejection
Interstitial Fibrosis, Kidney Transplant; Complications
Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation
This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of fingolimod (brand name Gilenya®, candidate name- FTY720) on the background of standard…
- Conditions
- Interstitial Fibrosis, Kidney Transplant; Complications, Kidney Transplant Rejection, Kidney Transplant Failure and Rejection
- Trial name
- NCT05285878
- Testing
- Fingolimod
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- The Methodist Hospital Research Institute
Prevention of Rejection in Kidney Transplant
Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.
- Trial name
- NCT05027906
- Testing
- AT-1501
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 48 people
- Sponsor
- Eledon Pharmaceuticals
Kidney Transplantation, Kidney Diseases
CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation
The advent of new, potent immunosuppressive (anti-rejection) drugs over the past ten years has substantially reduced the risk of rejection after kidney transplantation, has allowed the development of immuno-suppressive regimens…
- Conditions
- Kidney Transplantation, Kidney Diseases, Kidney Failure
- Trial name
- NCT00246129
- Testing
- Campath, Daclizumab
- Where
- United Kingdom
- Volunteers
- 123 people
- Sponsor
- EMagnusson
Kidney Transplant Rejection, Plasmapheresis
The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant
At present, the number of end-stage kidney disease patients is increasing. Kidney transplant surgery is one of the treatments that give patients a better survival rate than hemodialysis or abdominal dialysis.
- Conditions
- Kidney Transplant Rejection, Plasmapheresis, Kidney Replacement
- Trial name
- NCT03965559
- Testing
- plasmapheresis
- Volunteers
- 30 people
- Sponsor
- Chiang Mai University
Transplant; Failure, Kidney
Pilot Study of Contrast-Enhanced Ultrasound of Transplanted Kidney
To check the possibility of the acquisition of a number of parameters through real-time contrast-enhanced ultrasound and sonoelastography images and to verify the correlation with pathologic results from ultrasound guided biopsy…
- Trial name
- NCT01883583
- Testing
- Contrast-enhanced Ultrasound And Sonoelastography
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Seoul National University Hospital
Kidney Transplant Rejection
Evaluation of Patient Outcomes From the Kidney Allograft Outcomes AlloSure Registry
This is an observational study to evaluate safety and efficacy outcomes in renal transplant recipients in whom post-transplant care is managed using AlloSure®.
- Trial name
- KOAR (NCT03326076)
- Testing
- Donor-derived cell-free DNA (AlloSure®), Standard care, Peripheral blood gene expression profiling (AlloMap Kidney)
- Where
- 72 sites in United States
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- CareDx
Kidney Transplantation, Renal Transplantation
A Study to Evaluate FK778 in Kidney Transplant Patients
A dose finding study to evaluate the safety and effectiveness of FK778 in kidney transplant patients
- Conditions
- Kidney Transplantation, Renal Transplantation, Transplantation, Renal, Transplantation, Kidney
- Trial name
- NCT00189735
- Testing
- FK778
- Where
- 37 sites in Austria, Belgium and 10 more
- Volunteers
- 364 people
- Sponsor
- Astellas Pharma Inc
Kidney Transplant Rejection
Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab
Chronic active antibody mediated rejection (CAMR) is a therapeutic challenge in transplant recipients that does not respond well to conventional treatments for acute antibody mediated rejection (AMR).
- Trial name
- NCT07006532
- Testing
- Tocilizumab
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Renal Transplant Rejection, Renal Transplant Infection
NOMINATE/ Minimisation of Immunosuppression in Kidney Transplantation
Kidney transplantation provides the optimal form of kidney replacement therapy for the majority of people with end-stage kidney disease, and has now become the commonest form of kidney replacement therapy.
- Trial name
- NCT05073822
- Testing
- Tacrolimus
- Sponsor
- University College, London
Graft Rejection, Kidney Transplant
Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients
This study will look at the effect on long-term kidney function using tacrolimus right after a transplant and then switching to sirolimus at 3 to 5 months after the transplant.
- Conditions
- Graft Rejection, Kidney Transplant, Renal Allograft Recipients, Renal Transplant
- Trial name
- NCT00895583
- Testing
- Tacrolimus, Sirolimus
- Where
- 44 sites in United States, Argentina and 5 more
- Volunteers
- 254 people
- Sponsor
- Pfizer
Renal Transplant Rejection, Immune Repertoire
ALLoreactive T-Cell receptOr RePertoire in kidnEy tranSplantation
In this study, the investigators will establish a workflow to generate unique patterns of the donor-reactive T cell repertoire using mixed lymphocyte reactions to select alloreactive T cell clones prior to transplantation Tissue…
- Conditions
- Renal Transplant Rejection, Immune Repertoire, Transplant; Complication, Rejection, Alloreactivity
- Trial name
- ALL-T-COPIES (NCT03422224)
- Testing
- Mixed lymphocyte reaction
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Medical University of Vienna
Decreased Immunologic Activity, Antibody-mediated Rejection
Combined Apheresis for ABO-incompatible Transplantation - a Pilot Study
Recipient desensitization is a prerequisite for successful ABO-incompatible kidney transplantation (ABOi-KTX). Published desensitization protocols commonly include the use of plasmapheresis or selective (i.e.
- Trial name
- NCT02120482
- Testing
- Combined apheresis
- Where
- Austria
- Volunteers
- 4 people
- Sponsor
- Medical University of Vienna
Antibody Mediated Rejection
Cyclophosphamide Therapy for Refractory Antibody-Mediated Rejection (AMR) in Kidney Transplants
The study hypothesis is that short-term low dose cyclophosphamide therapy will be effective in resolving inflammation in patients with late phase antibody-mediated rejection refractory to current standard of care treatment.
- Trial name
- NCT01630538
- Testing
- Cyclophosphamide
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- University of Manitoba
Transplant;Failure,Kidney, Kidney Transplant
Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
This study will compare the performance of Gene Expression Profile (GEP)/ Donor derived cell free deoxyribonucleic acid (dd-cfDNA) tests, to the following tests: Molecular Microscope (MMDx) and histopathology (study of changes in…
- Conditions
- Transplant;Failure,Kidney, Kidney Transplant, Kidney Rejection Transplant
- Trial name
- NCT05811468
- Where
- United States
- Sponsor
- Rush University Medical Center
Kidney Transplant Rejection
Antithymocyte Globulin and Azathioprine Versus Basiliximab and Mycophenolate Mofetil in Living Donor Kidney Transplantation
Kidney transplantation is the best available treatment option for patients with end stage renal disease. However, kidney transplantation requires life-long use of immunosuppressive medication.
- Trial name
- NCT03789006
- Testing
- Antithymocyte Immunoglobulin (Rabbit), Interleukin 2 Receptor Antagonist
- Where
- Sudan
- Volunteers
- 300 people
- Sponsor
- University of Khartoum
DGF, Kidney Transplant; Complications
Highly Suppressive Treg in Delayed and Slow Graft Function After Kidney Transplantation
Delayed/slow graft function is the most common complication after kidney transplantation with an incidence over 20% and is the result of ischemia-reperfusion injury.
- Trial name
- NCT04414111
- Testing
- Highly suppressive Treg measurement
- Where
- 2 sites in United States
- Volunteers
- 180 people
- Sponsor
- St. Louis University
End-stage Renal Failure, Graft Rejection
Standard Versus Prolonged-release Tacrolimus Monotherapy After Alemtuzumab Induction in Kidney Transplantation
The current anti-rejection drug regime for kidney transplant recipients in use at the West London Renal \& Transplant Centre (WLRaTC) consists of induction therapy with the very potent monoclonal antibody Campath 1-H…
- Trial name
- TAESR (NCT00807144)
- Testing
- Tacrolimus (Kidney transplant maintenance immunosuppression), Kidney transplant maintenance immunosuppression
- Where
- United Kingdom
- Volunteers
- 102 people
- Sponsor
- Imperial College Healthcare NHS Trust
Kidney Transplant Infection, Kidney Transplant Rejection
Evaluation of Cell-mediated Immune Response by QuantiFERON Monitor® Assay in Kidney Transplant Recipients
All kidney transplant recipients require immunosuppression, the net level of which is difficult to assess. Current practice in assessing immune reactivity is to monitor levels of some immunosuppressive drugs.
- Trial name
- NCT03488771
- Where
- Croatia
- Volunteers
- 150 people
- Sponsor
- Clinical Hospital Merkur
Kidney Diseases
Mycophenolate Mofetil (MMF): A Long-Term Data Evaluation
The purposes of this study are: To review past clinical use of mycophenolate mofetil (MMF) in kidney transplant patients; To discover why doses were modified and how those modifications affected the survival and health of the…
- Trial name
- NCT00203671
- Volunteers
- 651 people
- Sponsor
- University of California, Los Angeles
Autoimmune Diseases
Pilot Trial to Assess Effect of CNI Conversion of Efalizumab on T Reg Cells
The purpose of this pilot trial is to determine whether a conversion from calcineurin inhibitors (CNI) and mycophenolate mofetil (MMF) to a regimen consisting of efalizumab and sirolimus is associated with an increase in T…
- Trial name
- NCT00777400
- Testing
- Efalizumab
- Where
- United States
- Sponsor
- University of California, San Francisco